Drugmaker Bristol-Myers Squibb has agreed to settle claims that it improperly marketed its antipsychotic drug Abilify by paying out $19.5 million to 42 states.

According to a statement from Pennsylvania Attorney General Bruce Beemer, the accord resolves litigation over allegations that the drugmaker improperly promoted the antipsychotic drug to elderly patients suffering from dementia, even though the drug had only been approved for treating schizophrenia. The complaint and settlement were in the Dauphin County Court of Common Pleas.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Advance® Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]